Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: Effects on health services utilisation

BMC Health Services Research

Volumn 10, Issue , 2010, Pages

  Robotin, Monica C ^a,b   Kansil, Melanie Q ^c   George, Jacob ^d,e   Howard, Kirsten ^a   Tipper, Steven ^b   Levy, Miriam ^f,g   Phung, Nghi ^h   Penman, Andrew G ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CANCER RESEARCH DIVISION   (Australia)

^c Centaurus Partners   (Australia)

^d Millennium Institute   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f LIVERPOOL HOSPITAL   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUSTRALIA; CHINA; ETHNOLOGY; HEALTH SERVICE; HEALTH SURVEY; HEPATITIS B; HONG KONG; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MASS SCREENING; METHODOLOGY; MIDDLE AGED; UTILIZATION REVIEW; VIET NAM;

CARCINOMA, HEPATOCELLULAR; CHINA; HEALTH SERVICES; HEPATITIS B, CHRONIC; HONG KONG; HUMANS; LIVER NEOPLASMS; MASS SCREENING; MIDDLE AGED; NEW SOUTH WALES; POPULATION SURVEILLANCE; VIETNAM;

EID: 77954674906     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-10-215     Document Type: Article

References (37)

1. N Alam W Chen D Baker J Bishop, Liver Cancer in New South Wales C. I. NSW. Sydney: Cancer Institute NSW 2009
2. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Amin GJ Dore DL O'Connell M Bartlett E Tracey JM Kaldor MG Law, J Hepatol 2006 45 2 197 203 10.1016/j.jhep.2006.02.014 16684579
3. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial. RP Beasley LY Hwang CC Lin CE Stevens KY Wang TS Sun FJ Hsieh W Szmuness, Lancet 1981 2 8243 388 93 6115159
4. Primary liver cancer: worldwide incidence and trends. FX Bosch J Ribes M Diaz R Cleries, Gastroenterology 2004 127 5 Suppl 1 5 S16 10.1053/j.gastro.2004. 09.011 15508102
5. Hepatocellular carcinoma in Sydney South West: late symptomatic presentation and poor outcome for most. L Gellert B Jalaludin M Levy, Internal Medicine Journal 2007 37 8 516 22 10.1111/j.1445-5994.2007.01392.x 17543001
6. G Dore J Wallace S Locarnini P Desmond E Gane DH Crawford, Hepatitis B in Australia: responding to a diverse epidemic Sydney 2006
7. Liver cancer and hepatitis B and C in New South Wales, 1990-2002: a linkage study. J Amin D O'Connell M Bartlett E Tracey J Kaldor M Law G Dore, Aust N Z J Public Health 2007 31 5 475 82 10.1111/j.1753-6405.2007.00121.x 17931297
8. Cancer incidence in New South Wales migrants 1991 to 2001. R Supramaniam DL O'Connell E Tracey F Sitas, Sydney: The Cancer Council NSW 2006
9. Randomized controlled trial of screening for hepatocellular carcinoma. BH Zhang BH Yang ZY Tang, J Cancer Res Clin Oncol 2004 130 7 417 22 10.1007/s00432-004-0552-0 15042359
10. Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B. YT Wun JA Dickinson, Cochrane Database Syst Rev 2003 2 D002799 12804438
11. Treatment of chronic hepatitis B: who to treat, what to use, and for how long? SK Fung AS Lok, Clin Gastroenterol Hepatol 2004 2 10 839 48 10.1016/S1542-3565(04)00386-6 15476146
12. Lamivudine treatment in patients with chronic hepatitis B and cirrhosis. C Hache JP Villeneuve, Expert Opin Pharmacother 2006 7 13 1835 43 10.1517/14656566.7.13.1835 16925509
13. Chronic hepatitis B: update of recommendations. AS Lok BJ McMahon, Hepatology 2004 39 3 857 61 10.1002/hep.20110 14999707
14. HIV/AIDS, viral hepatitis and sexually transmitted infections in Australia. Annual Surveillance Report. National Centre in HIV Epidemiology and Clinical Research, NCHECR Research. Sydney: National Centre in HIV Epidemiology and Clinical Research 2007
15. The NSW HBV and liver cancer pilot program: an update on the 'B Positive' Project. S Tipper AG Penman, Cancer Forum 2009 33 2
16. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. EB Keeffe DT Dieterich SH Han IM Jacobson P Martin ER Schiff H Tobias TL Wright, Clin Gastroenterol Hepatol 2006 4 8 936 62 10.1016/j.cgh.2006.05.016 16844425
17. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. YF Liaw N Leung R Guan GK Lau I Merican G McCaughan E Gane JH Kao M Omata, Liver Int 2005 25 3 472 89 10.1111/j.1478-3231.2005.01134.x 15910483
18. Best practice in the treatment of chronic hepatitis B: a summary of the European Viral Hepatitis Educational Initiative (EVHEI). HC Thomas, J Hepatol 2007 47 4 588 97 10.1016/j.jhep.2007.07.017 17697725
19. Estimates and projections of hepatitis B-related hepatocellular carcinoma in Australia among people born in Asia-Pacific countries. VT Nguyen K Razali J Amin MG Law GJ Dore, J Gastroenterol Hepatol 2008 23 6 922 9 10.1111/j.1440-1746.2007.05065.x 17608637
20. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. MC Robotin M Kansil K Howard J George S Tipper GJ Dore M Levy AG Penman, J Hepatol 2009 50 5 990 8 10.1016/j.jhep.2008. 12.022 19303657
21. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. L Bolondi S Sofia S Siringo S Gaiani A Casali G Zironi F Piscaglia L Gramantieri M Zanetti M Sherman, Gut 2001 48 2 251 9 10.1136/gut.48.2.251 11156649
22. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. CJ Chen HI Yang J Su CL Jen SL You SN Lu GT Huang UH Iloeje, Jama 2006 295 1 65 73 10.1001/jama.295.1.65 16391218
23. Pathogenesis and screening for hepatocellular carcinoma. M Sherman, Clin Liver Dis 2004 8 2 419 43 viii 10.1016/j.cld.2004.02.002 15481348
24. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. F Kanwal IM Gralnek P Martin GS Dulai M Farid BM Spiegel, Ann Intern Med 2005 142 10 821 31 15897532 (Pubitemid 40664041)
25. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. J Shepherd J Jones A Takeda P Davidson A Price, Health Technol Assess 2006 10 28 ii iv xi-xiv, 1-183 16904047
26. The New Zealand Hepatitis B Screening Programme: screening coverage and prevalence of chronic hepatitis B infection. T Robinson C Bullen W Humphries J Hornell C Moyes, N Z Med J 2005 118 1211 1345 15778747
27. Risk perceptions and barriers to Hepatitis B screening and vaccination among Vietnamese immigrants. GX Ma CY Fang SE Shive J Toubbeh Y Tan P Siu, J Immigr Minor Health 2007 9 3 213 20 10.1007/s10903-006-9028-4 17265128
28. Cervical screening among immigrant Vietnamese women seen in general practice: current rates, predictors and potential recruitment strategies. M Lesjak M Hua J Ward, Aust N Z J Public Health 1999 23 2 168 73 10.1111/j.1467-842X.1999.tb01229.x 10330732
29. Referral of chronic hepatitis B patients from primary to specialist care: making a simple guideline work. MC Mostert JH Richardus RA de Man, J Hepatol 2004 41 6 1026 30 10.1016/j.jhep.2004.08.012 15582137
30. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. VT Nguyen MG Law GJ Dore, J Viral Hepat 2009 16 7 453 63 10.1111/j.1365-2893.2009.01117.x 19302335
31. Overweight and obesity in Australia: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). AJ Cameron TA Welborn PZ Zimmet DW Dunstan N Owen J Salmon M Dalton D Jolley JE Shaw, Med J Aust 2003 178 9 427 32 12720507
32. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. EE Calle C Rodriguez K Walker-Thurmond MJ Thun, N Engl J Med 2003 348 17 1625 38 10.1056/NEJMoa021423 12711737
33. Smoking and liver cancer in China: case-control comparison of 36,000 liver cancer deaths vs. 17,000 cirrhosis deaths. ZM Chen BQ Liu J Boreham YP Wu JS Chen R Peto, Int J Cancer 2003 107 1 106 12 10.1002/ijc.11342 12925964
34. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. F Donato A Tagger U Gelatti G Parrinello P Boffetta A Albertini A Decarli P Trevisi ML Ribero C Martelli S Porru G Nardi, Am J Epidemiol 2002 155 4 323 31 10.1093/aje/155.4.323 11836196
35. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. YH Ni MH Chang KJ Wang HY Hsu HL Chen JH Kao SH Yeh YM Jeng KS Tsai DS Chen, Gastroenterology 2004 127 6 1733 8 10.1053/j.gastro.2004.09.048 15578511
36. Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. DL White D Li Z Nurgalieva HB El-Serag, Am J Epidemiol 2008 167 4 377 89 10.1093/aje/kwm315 18065725
37. Australia's Health Workforce, Research Report. Productivity Commission, Canberra: Commonwealth of Australia 2005